Brazilian Scientist’s Blood Test Breakthrough Offers New Hope in Alzheimer’s Diagnosis
A 28-year-old Brazilian physician and researcher, Wagner Scheeren Brum, has received international recognition for his groundbreaking work on a blood test that could revolutionize Alzheimer’s disease diagnosis. The award, the AAIC Neuroscience Next “One to Watch” Award 2026, from the Alzheimer’s Association, highlights the potential of this research to transform how we identify and treat this devastating disease.
The Promise of p-tau217
Brum’s research centers on the protein p-tau217, a biomarker that indicates early brain changes associated with Alzheimer’s. Currently, Alzheimer’s diagnosis relies heavily on clinical evaluation, a process that, while essential, has limitations. More precise tests, like PET scans and cerebrospinal fluid analysis, exist but are expensive, invasive, and not widely accessible, particularly in Brazil.
“There isn’t a widely available test in Brazil to evaluate whether patients clinically diagnosed with Alzheimer’s possess a characteristic molecular signature in the brain,” explains Brum.
A Two-Step Diagnostic Workflow
The innovative approach developed by Brum involves a “two-step” workflow. A blood-based model incorporating p-tau217 levels, age, and APOE ε4 status is used to categorize patients into low, intermediate, or high risk of Alzheimer’s pathology. Patients identified as intermediate risk would then undergo further testing, such as cerebrospinal fluid analysis, while those in the low and high-risk groups could receive a diagnosis based solely on the blood test results.
Studies have shown this method can significantly reduce the number of confirmatory tests needed while maintaining high accuracy. One study demonstrated an overall accuracy of up to 92.0% in detecting Aβ-PET status, reducing the need for CSF tests by as much as 85.9% depending on the thresholds used.
Addressing Global Challenges in Alzheimer’s Diagnosis
Brum’s work is particularly significant because it addresses a critical need for cost-effective and accessible diagnostic tools. The scarcity of specialized professionals for cognitive assessments and limited access to imaging technologies further underscore the importance of a reliable blood test.
“Being part of the movement of Brazilian researchers who are changing international paradigms is something that makes me very proud,” Brum stated, acknowledging the historical dominance of North American and European research in the field.
Implementation and Future Directions
The p-tau217 blood test is currently being implemented in various countries. A key challenge is adapting the test to existing hospital equipment to ensure consistent results across different laboratories. Another crucial step is validating the test’s effectiveness in diverse populations beyond Europe and North America, where most studies have been conducted.
“One of the challenges is to display that the test also works in patients with Alzheimer’s in the Global South,” Brum emphasizes.
The ultimate goal is to integrate this technology into clinical practice, empowering physicians – including neurologists and geriatricians – to diagnose and manage Alzheimer’s disease more effectively.
FAQ
Q: What is the p-tau217 protein?
A: p-tau217 is a biomarker found in the blood that can indicate early brain changes associated with Alzheimer’s disease.
Q: How does this blood test differ from current Alzheimer’s diagnosis methods?
A: Current methods often rely on clinical evaluation or expensive and invasive tests. This blood test offers a potentially more accessible and cost-effective alternative.
Q: Is this test currently available to patients?
A: The test is in the process of being implemented in different countries and is not yet widely available.
Q: What is the “two-step” workflow?
A: It’s a diagnostic approach where a blood test categorizes patients into risk levels, and only those at intermediate risk undergo further, more intensive testing.
Q: Where is Wagner Scheeren Brum conducting his research?
A: He is a doctoral candidate at the Universidade Federal do Rio Grande do Sul (UFRGS) and a member of the Zimmer Lab.
Pro Tip: Early detection is crucial for managing Alzheimer’s disease. Discuss any concerns you have with your doctor.
Did you understand? The Zimmer Lab has now had four scientists receive the AAIC Neuroscience Next “One to Watch” Award.
Stay informed about the latest advancements in Alzheimer’s research. Explore more articles on our website or subscribe to our newsletter for regular updates.
